The European Patent Office (EPO) has granted patent EP3560519B1, concerning a genetic treatment method utilizing Virus AAV/IGF2 for protein misfolding-related diseases, including Huntington's disease. This grant signifies the EPO's recognition of the novelty and inventiveness of the claimed method and its therapeutic applications.

This patent grant is primarily of interest to pharmaceutical and biotechnology companies involved in gene therapy and the development of treatments for neurological disorders. While it does not impose new regulatory obligations on these entities, it establishes intellectual property rights that may influence research and development strategies, licensing agreements, and market exclusivity for related therapies within the designated European states.